Hasil untuk "Life"

L. Cabeza, L. Rincón, Virginia Vilariño et al.

Joseph A Hill

S. Nik-Zainal, Peter Van Loo, D. Wedge et al.

Summary Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis. PaperClip

P. Qualter, J. Vanhalst, Rebecca A. Harris et al.

Victoria Dickinson

J. Guinée, R. Heijungs, G. Huppes et al.

G. Guyatt, D. Feeny, D. Patrick

P. Gourinchas, J. Parker

Phyllis M. Bartlow

R. Sugden, M. Nussbaum, Amartya Sen

D. Acemoglu, Simon Johnson

João F. Cocco, Francisco Gomes, Pascal J. Maenhout

A. Nilsdotter, L. S. Lohmander

K. Motamedi

J. Greenhaus, K. Collins, J. Shaw

E. Juniper, G. Guyatt, A. Willan et al.

R. Margalef

A. Kanner, J. Coyne, Catherine Schaefer et al.

J. Aburto, Francisco Villavicencio, Ugofilippo Basellini et al.

Significance Why life expectancy and life span equality have increased together is a question of scientific interest. Both measures are calculated for a calendar year and might not describe a cohort’s actual life course. Nonetheless, life expectancy provides a useful measure of average life spans, and life span equality gives insights into uncertainty about age at death. We show how patterns of change in life expectancy and life span equality are described by trajectories of mortality improvements over age and time. The strength of the relationship between life expectancy and life span equality is not coincidental but rather a result of progress in saving lives at specific ages: the more lives saved at the youngest ages, the stronger the relationship is. As people live longer, ages at death are becoming more similar. This dual advance over the last two centuries, a central aim of public health policies, is a major achievement of modern civilization. Some recent exceptions to the joint rise of life expectancy and life span equality, however, make it difficult to determine the underlying causes of this relationship. Here, we develop a unifying framework to study life expectancy and life span equality over time, relying on concepts about the pace and shape of aging. We study the dynamic relationship between life expectancy and life span equality with reliable data from the Human Mortality Database for 49 countries and regions with emphasis on the long time series from Sweden. Our results demonstrate that both changes in life expectancy and life span equality are weighted totals of rates of progress in reducing mortality. This finding holds for three different measures of the variability of life spans. The weights evolve over time and indicate the ages at which reductions in mortality increase life expectancy and life span equality: the more progress at the youngest ages, the tighter the relationship. The link between life expectancy and life span equality is especially strong when life expectancy is less than 70 y. In recent decades, life expectancy and life span equality have occasionally moved in opposite directions due to larger improvements in mortality at older ages or a slowdown in declines in midlife mortality. Saving lives at ages below life expectancy is the key to increasing both life expectancy and life span equality.

Adam P Wagner, Nicholas J Simmonds, Susan C Charman et al.

Introduction Yoga is an emerging exercise choice for people with cystic fibrosis (CF), but evidence of its effect in this population is scarce, with a recent systematic review advocating for further research. Yoga Outcomes Get Assessed in CF (YOGA-CF) is a real-world multicentre randomised controlled trial (RCT) investigating a bespoke CF-specific online 12-week yoga intervention, vers usual care, to determine effectiveness for adults with CF.Methods and analysis A multicentre RCT of adults with CF across the UK. Participants are randomised to usual care or a 12-week online bespoke yoga programme with an expectation of two classes completed weekly. Assessments of lung function, 1 min sit-to-stand, the Cystic Fibrosis Questionnaire-Revised (CFQ-R) and other trial questionnaires are completed preintervention and postintervention (0 and 12 weeks) and after 12 weeks of follow-up (week 24). The primary outcome is the difference in respiratory-related quality of life measured using the CFQ-R before and after yoga/control. Sample size was calculated based on detecting a minimally clinically important difference of 4 for the CFQ-R respiratory domain, with power of 80% and 5% significance level (total target, n=314).Ethics and dissemination Ethics approval gained from the South Yorkshire and Humber Research Ethics Committee (REC) (reference: 23/YH/0270, project ID 303898). Dissemination to involve direct participant feedback and lay webinar, scientific conference presentation and publication in a peer-reviewed journal.Trial registration number NCT06120465.